Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colby Pharmaceutical Co.

This article was originally published in Start Up

Executive Summary

Colby Pharmaceutical aims to develop drugs capable of inhibiting key enzymatic and hormonal signaling pathways in prostate and brain cancers. The start-up hopes to help men who have been diagnosed with primary or recurrent prostate cancer, including those who have failed current standard of care hormone therapy or chemotherapy. The company's lead compound is an anti-inflammatory and anti-androgenic small molecule that binds the androgen receptor. In culture and in animals, Colby says that it is therapeutic for androgen-dependent prostate tumors. The molecule does not appear to be pro-estrogenic and CPC-100 is also therapeutic for androgen-independent prostate tumors-which would distinguish it from all other anti-androgens now on the market.

You may also be interested in...



Med Discovery SA

Switzerland's Med Discovery was founded on the discovery of a prostate cancer target, human kallikrein 2, a key protease associated with prostate biology that is thought to contribute to cancer progression and development. The start-up's lead protease inhibitor targets hK2 and is based on the natural serine protease inhibitor ACT, which the company believes will avoid the selectivity and toxicities of other protease inhibitors. Med Discovery is developing the candidate for prostate cancer, but it believes it also has potential for treating skin disorders and for immunological treatment of cancer.

Treating Late-Stage Prostate Cancer

Prostate cancer was the cause of 28,666 deaths in 2008, or 10% of cancer deaths in the US, and roughly 186,000 men are diagnosed with the disease each year. Docetaxel, a chemotherapeutic agent, is the only FDA-approved drug to treat late-stage prostate cancer, leaving a significant need that many biotechs and pharmaceutical firms are trying to meet. Results are starting to roll in from several key clinical trials of late-stage prostate cancer therapies. Start-ups embarking on drug development may face significant competition.

Bellicum Pharmaceuticals Inc.

Bellicum Pharmaceuticals is developing a therapeutic vaccine for late-stage prostate cancer. The start-up believes that one of the reasons vaccines have floundered in the clinic may be negative feedback loops that desensitize the vaccine before it's had a chance to work. Bellicum's autologous vaccine is designed to avoid that. Its dimerizer agent is injected 24 hours after the vaccine, giving the dendritic cells time to migrate to draining lymph nodes before activation. When therapeutic vaccine cells are stimulated ex-vivo, they begin releasing key cytokines, such as IL-12, immediately.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091752

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel